Bifogade filer
Results from Orviglance comparison study to gadolinium presented at ESGAR 2022 conference
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Ascelia Pharma AB (publ) (ticker: ACE) today presented results at the annual ESGAR conference in Lisbon, Portugal, from the study in which the investigational contrast agent Orviglance® was compared to a gadolinium-based contrast agent.
“We are very pleased to have presented the study as an oral scientific presentation at the respected European Society of Gastrointestinal and Abdominal Radiology (ESGAR) annual conference. The study provides robust evidence of the diagnostic value that Orviglance can offer once it is available to patients and physicians.”, said Carl Bjartmar, Chief Medical Officer at Ascelia Pharma.
As communicated earlier, the results showed that a higher number of liver lesions was detected by the three independent readers for Orviglance compared to the liver-specific gadolinium contrast agent. All three readers were also able to see smaller lesions with Orviglance compared to gadolinium. With respect to lesion border delineation and lesion contrast to liver, two out of three readers reported higher scores for Orviglance compared to gadolinium.
While the efficacy parameters show higher scores for Orviglance, this crossover study was comprised only of 20 patients with liver metastases and hence the difference was not statistically significant.
The results also showed that Orviglance-enhanced MRI provides improved efficacy in terms of lesion detection and visualization compared to MRI without a contrast agent.